Trial intelligence / Profile preview

Etanercept dose reduction or withdrawal versus methotrexate alone after induction in moderate rheumatoid arthritis

2007-000896-41Phase 4Completed

Sponsor
Wyeth
Start
Oct 2007
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, randomised, double-blind trial of etanercept and methotrexate in rheumatoid arthritis (RA) (3 arms), sponsored by Wyeth. Started Oct 2007; status: completed.

02

Drugs

etanerceptmethotrexate
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on 2007-000896-41.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-000896-41.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call